Cargando…

Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging

BACKGROUND: The sensitive and specific detection of pathogenic cells is important in tumor diagnosis at an early stage. Aptamers are short single-stranded oligonucleotides evolved from systematic evolution of ligands by exponential enrichment (SELEX). It has been proved that aptamers can interact wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jinman, Ding, Jianke, Deng, Lei, Xiang, Ying, Liu, Duoduo, Zhang, Yanyan, Chen, Xin, Yang, Quanxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464308/
https://www.ncbi.nlm.nih.gov/pubmed/34584404
http://dx.doi.org/10.2147/DDDT.S322854
_version_ 1784572603167408128
author Zhong, Jinman
Ding, Jianke
Deng, Lei
Xiang, Ying
Liu, Duoduo
Zhang, Yanyan
Chen, Xin
Yang, Quanxin
author_facet Zhong, Jinman
Ding, Jianke
Deng, Lei
Xiang, Ying
Liu, Duoduo
Zhang, Yanyan
Chen, Xin
Yang, Quanxin
author_sort Zhong, Jinman
collection PubMed
description BACKGROUND: The sensitive and specific detection of pathogenic cells is important in tumor diagnosis at an early stage. Aptamers are short single-stranded oligonucleotides evolved from systematic evolution of ligands by exponential enrichment (SELEX). It has been proved that aptamers can interact with cognate target molecules with high affinity and specificity and have great potential in the development of medical imaging at molecular level. PURPOSE: To select epithelial cell adhesion molecule (EpCAM) specific aptamers targeting prostate cancer and further to conjugate aptamers with GoldMag nanoparticles (a typical iron oxide core/gold shell structure) to construct magnetic molecular probes for medical imaging. METHODS: EpCAM-specific aptamers were selected by Cell-SELEX. The enrichment of specific aptamer candidates was monitored by flow cytometric analysis. Aptamers were further conjugated with GoldMag nanoparticles to construct magnetic molecular probes. The affinity and specificity of aptamer candidates and aptamer-conjugated GoldMag nanoparticles were evaluated. The MR imaging of aptamer-conjugated GoldMag nanoparticles to prostate cancer was further explored in vitro and in vivo. RESULTS: After 12 rounds of selection, aptamer candidates Eppc6 and Eppc14 could specifically target three types of prostate cancer cells, revealing a high affinity of Eppc6 and Eppc14. Moreover, aptamer-conjugated GoldMag nanoparticles not only exhibited good affinity to different prostate cancer cells but also produced strong T2WI signal intensity reduction distinguished from peritumoral tissue in MRI, indicating that the molecular probes possess both the affinity properties of EpCAM-specific aptamer and the superparamagnetic features of iron oxide. CONCLUSION: Our study indicates that aptamer Eppc6 and Eppc14 can recognize prostate cancer cells and tissues. The aptamer-conjugated GoldMag nanoparticles constructed in the study can be used as a molecular imaging agent for detection of PCa in MRI.
format Online
Article
Text
id pubmed-8464308
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84643082021-09-27 Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging Zhong, Jinman Ding, Jianke Deng, Lei Xiang, Ying Liu, Duoduo Zhang, Yanyan Chen, Xin Yang, Quanxin Drug Des Devel Ther Original Research BACKGROUND: The sensitive and specific detection of pathogenic cells is important in tumor diagnosis at an early stage. Aptamers are short single-stranded oligonucleotides evolved from systematic evolution of ligands by exponential enrichment (SELEX). It has been proved that aptamers can interact with cognate target molecules with high affinity and specificity and have great potential in the development of medical imaging at molecular level. PURPOSE: To select epithelial cell adhesion molecule (EpCAM) specific aptamers targeting prostate cancer and further to conjugate aptamers with GoldMag nanoparticles (a typical iron oxide core/gold shell structure) to construct magnetic molecular probes for medical imaging. METHODS: EpCAM-specific aptamers were selected by Cell-SELEX. The enrichment of specific aptamer candidates was monitored by flow cytometric analysis. Aptamers were further conjugated with GoldMag nanoparticles to construct magnetic molecular probes. The affinity and specificity of aptamer candidates and aptamer-conjugated GoldMag nanoparticles were evaluated. The MR imaging of aptamer-conjugated GoldMag nanoparticles to prostate cancer was further explored in vitro and in vivo. RESULTS: After 12 rounds of selection, aptamer candidates Eppc6 and Eppc14 could specifically target three types of prostate cancer cells, revealing a high affinity of Eppc6 and Eppc14. Moreover, aptamer-conjugated GoldMag nanoparticles not only exhibited good affinity to different prostate cancer cells but also produced strong T2WI signal intensity reduction distinguished from peritumoral tissue in MRI, indicating that the molecular probes possess both the affinity properties of EpCAM-specific aptamer and the superparamagnetic features of iron oxide. CONCLUSION: Our study indicates that aptamer Eppc6 and Eppc14 can recognize prostate cancer cells and tissues. The aptamer-conjugated GoldMag nanoparticles constructed in the study can be used as a molecular imaging agent for detection of PCa in MRI. Dove 2021-09-21 /pmc/articles/PMC8464308/ /pubmed/34584404 http://dx.doi.org/10.2147/DDDT.S322854 Text en © 2021 Zhong et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhong, Jinman
Ding, Jianke
Deng, Lei
Xiang, Ying
Liu, Duoduo
Zhang, Yanyan
Chen, Xin
Yang, Quanxin
Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging
title Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging
title_full Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging
title_fullStr Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging
title_full_unstemmed Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging
title_short Selection of DNA Aptamers Recognizing EpCAM-Positive Prostate Cancer by Cell-SELEX for in vitro and in vivo MR Imaging
title_sort selection of dna aptamers recognizing epcam-positive prostate cancer by cell-selex for in vitro and in vivo mr imaging
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464308/
https://www.ncbi.nlm.nih.gov/pubmed/34584404
http://dx.doi.org/10.2147/DDDT.S322854
work_keys_str_mv AT zhongjinman selectionofdnaaptamersrecognizingepcampositiveprostatecancerbycellselexforinvitroandinvivomrimaging
AT dingjianke selectionofdnaaptamersrecognizingepcampositiveprostatecancerbycellselexforinvitroandinvivomrimaging
AT denglei selectionofdnaaptamersrecognizingepcampositiveprostatecancerbycellselexforinvitroandinvivomrimaging
AT xiangying selectionofdnaaptamersrecognizingepcampositiveprostatecancerbycellselexforinvitroandinvivomrimaging
AT liuduoduo selectionofdnaaptamersrecognizingepcampositiveprostatecancerbycellselexforinvitroandinvivomrimaging
AT zhangyanyan selectionofdnaaptamersrecognizingepcampositiveprostatecancerbycellselexforinvitroandinvivomrimaging
AT chenxin selectionofdnaaptamersrecognizingepcampositiveprostatecancerbycellselexforinvitroandinvivomrimaging
AT yangquanxin selectionofdnaaptamersrecognizingepcampositiveprostatecancerbycellselexforinvitroandinvivomrimaging